Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Pathological complete response after neoadjuvant chemotherapy with trastuzumabcontaining regimen in gastric cancer: a case report | Wang et al. Journal of Hematology Oncology 2010 3 31 http content 3 1 31 JOURNAL OF HEMATOLOGY ONCOLOGY CASE REPORT Open Access Pathological complete response after neoadjuvant chemotherapy with trastuzumabcontaining regimen in gastric cancer a case report 11 2 3 4 Jun Wang George W Saukel Carlos A Garberoglio Wichit Srikureja Chung-Tsen Hsueh Abstract We report a 49-year-old Chinese male with locally advanced gastric adenocarcinoma achieving pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen. He underwent esophagogastroduodenoscopy in September 2009 which revealed a 2-cm gastric ulcer on the lesser curvature proximal to angularis. Biopsy of gastric ulcer showed moderately differentiated adenocarcinoma with overexpression of human epidermal growth factor receptor 2 HER2 by immunohistochemistry and fluorescence in situ hybridization. Further workups with endoscopic ultrasound computed tomography and positron emission tomography staged his cancer as T3N1M0. He received 3 cycles of neoadjuvant chemotherapy consisting of trastuzumab oxaliplatin docetaxel and capecitabine without severe toxicities except grade 2 diarrhea near the completion of cycle 3 requiring discontinuation of capecitabine. Afterwards he received total gastrectomy with extended D2 lymph node dissections showing pathological complete response. He went on to receive 3 more cycles of chemotherapy postoperatively. The role of trastuzumab as a part of perioperative therapy in gastric cancer overexpressing HER2 is worth further investigation. Introduction Gastric cancer is the fourth most common cancer worldwide with overall 5-year survival rate of approximate 20 representing a significant challenge for the treating physicians 1 . Perioperative chemotherapy has been shown to cause tumor downstaging and improve survival in patients with resectable gastric cancer 2 . Response to neoadjuvant treatment is the most important predictor of survival
